A role for Danazol in chronic lymphocytic leukemia

Stephanie Tung, David Spaner
In: Leukemia · 2012 · vol. 26(7) , pp. 1684–1686 · doi:10.1038/leu.2011.386 · PMID:22289992 · W1995819138
letter OA: closed CC0 ⤵ 2 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-09 ⓘ

Danazol demonstrated cytotoxicity in chronic lymphocytic leukemia cells, particularly when combined with dexamethasone, including those with the 17p deletion abnormality.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This paper examined the in vitro effects of danazol on chronic lymphocytic leukemia (CLL) cells, focusing particularly on tumor cells carrying 17p deletions and comparing them with CLL cells lacking this cytogenetic abnormality. The authors reported that danazol at 10 μM could kill 17p− cells, with enhanced killing observed when danazol was combined with dexamethasone (Dex), although 17p− cells appeared less sensitive than cells without 17p deletions and the differences were not statistically significant. A key caveat was that the results for the 17p− condition used cryopreserved cells, and higher spontaneous death after thawing reduced the observed specific death levels compared with experiments using fresh tumor cells. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 4,877 characters · extracted from oa-doi-fallback · 2 sections · click to expand

References

Gribben JG, O'Brien S . Update on therapy of CLL. J Clin Oncol 2011; 29: 544–550. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in combination with high-dose methylprednisolone for the treatment of CLL. Leukemia 2009; 23: 1779–1789. Fontana V, Dudkiewicz P, Ahn ER, Horstman L, Ahn YS . Danazol therapy combined with intermittent application of chemotherapy induces lasting remission in myeloproliferative disorder (MPD). Hematology 2011; 16: 90–94. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A . Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82: 274–281. Morcavallo PS, Leonida A, Rossi G, Mingardi M, Martini M, Monguzzi R et al. Hereditary angioedema in oral surgery. J Oral Maxillofac Surg 2010; 68: 2307–2311. Johanssen S, Allolio B . Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157: 561–569. Spaner DE . Oral high-dose glucocorticoids and ofatumumab in flurarabine-resistant chronic lymphocytic leukemia. Leukemia 2011; e-pub ahead of print 8 November 2011; doi:10.1038/leu.2011.329. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB . Multiagent induction and maintenance therapy for patients with refractory ITP. Blood 2007; 110: 3526–3531. Shepherd J . Danazol and plasma lipoprotein metabolism. Int J Gynaecol Obstet 1995; 50 (Suppl 1): S23–S26. Alvarez G, Gómez-Galicia D, Rodríguez-Fragoso L, Marina V, Dorantes L, Sánchez-Alemán M et al. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Ann Hepatol 2011; 10: 458–468. Matalliotakis I, Neonaki M, Koumantaki Y, Goumenou A, Kyriakou D, Koumantakis E . A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. Obstet Gynecol 2000; 95: 810–813. Tomic J, Lichty B, Spaner DE . Aberrant interferon-signaling is associated with aggressive CLL. Blood 2011; 117: 2668–2680. Tanaka T . Danazol regulates the functions of normal human endometrial stromal cell subpopulations by modifying endometrial cytokine networks. Int J Mol Med 2009; 23: 421–428. Horstman L, Jy W, Arce M, Ahn YS . Danazol distribution in plasma and cell membranes as related to altered cell properties: implications for mechanism. Am J Hematol 1995; 50: 179–187.

Acknowledgements

This study was supported by the Canadian Institutes of Health Research (CIHR) and the Leukemia and Lymphoma Society of Canada (to DS) and a QEII-SST graduate scholarship from the University of Toronto (to ST). Author information Authors and Affiliations Corresponding author Ethics declarations Competing interests The authors declare no conflict of interest. Rights and permissions About this article Cite this article Tung, S., Spaner, D. A role for Danazol in chronic lymphocytic leukemia. Leukemia 26, 1684–1686 (2012). https://doi.org/10.1038/leu.2011.386 Published: Issue date: DOI: https://doi.org/10.1038/leu.2011.386

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (14)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-10T10:47:52.373991+00:00
License: CC0 · commercial use OK